AI Article Synopsis

  • The study analyzed the effects of transjugular intrahepatic portosystemic shunt (TIPS) on waitlist mortality and liver transplantation access in Budd-Chiari Syndrome (BCS) patients using the UNOS database from 2002 to 2024.
  • Among 815 BCS patients, those who received TIPS had lower severity scores, lesser urgent statuses, and longer waitlist times for liver transplants compared to non-TIPS patients.
  • The findings revealed that while TIPS use increased over time and led to improved medical conditions at the time of transplantation, it was associated with lower access to liver transplantation and a lower risk of waitlist mortality.

Article Abstract

The impact of TIPS on waitlist mortality and liver transplantation (LT) urgency in patients with Budd-Chiari syndrome (BCS) remains unclear. We analyzed patients with BCS listed for LT in the UNOS database (2002-2024) to assess TIPS's impact on waitlist mortality and LT access through competing-risk analysis. We compared trends across 2 phases: phase 1 (2002-2011) and phase 2 (2012-2024). Of 815 patients with BCS, 263 (32.3%) received TIPS at listing. TIPS group had lower MELD-Na scores (20 vs. 22, p < 0.01), milder ascites ( p = 0.01), and fewer Status 1 patients (those at risk of imminent death while awaiting LT) (2.7% vs. 8.3%, p < 0.01) at listing compared to those without TIPS. TIPS patients had lower LT rates (43.3% vs. 56.5%, p < 0.01) and longer waitlist times (350 vs. 113 d, p < 0.01). TIPS use increased in phase 2 (64.3% vs. 35.7%, p < 0.01). Of 426 patients who underwent transplantation, 134 (31.5%) received TIPS, showing lower MELD-Na scores (24 vs. 27, p < 0.01) and better medical conditions (intensive care unit: 14.9% vs. 21.9%, p < 0.01) at LT. Status 1 patients were fewer (3.7% vs. 12.3%, p < 0.01), with longer waiting days (97 vs. 26 d, p < 0.01) in the TIPS group. TIPS use at listing increased from phase 1 (25.6%) to phase 2 (37.7%). From phase 1 to phase 2, ascites severity improved, re-LT cases decreased (phase 1: 9.8% vs. phase 2: 2.2%, p < 0.01), and cold ischemic time slightly decreased (phase 1: 7.0 vs. phase 2: 6.4 h, p = 0.14). Median donor body mass index significantly increased. No significant differences were identified in patient/graft survival at 1-/5-/10-year intervals between phases or TIPS/non-TIPS patients. While 90-day waitlist mortality showed no significant difference ( p = 0.11), TIPS trended toward lower mortality (subhazard ratio [sHR]: 0.70 [0.45-1.08]). Multivariable analysis indicated that TIPS was a significant factor in decreasing mortality (sHR: 0.45 [0.27-0.77], p < 0.01). TIPS group also showed significantly lower LT access (sHR: 0.65 [0.53-0.81], p < 0.01). Multivariable analysis showed that TIPS was a significant factor in decreasing access to LT (sHR: 0.60 [0.46-0.77], p < 0.01). Subgroup analysis excluding Status 1 or HCC showed similar trends. TIPS in patients with BCS listed for LT reduces waitlist mortality and LT access, supporting its bridging role.

Download full-text PDF

Source
http://dx.doi.org/10.1097/LVT.0000000000000469DOI Listing

Publication Analysis

Top Keywords

waitlist mortality
20
tips
15
001
14
mortality access
12
patients bcs
12
tips group
12
001 tips
12
phase
11
patients
9
liver transplantation
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!